Pender Fund Capital Management Ltd. 89bio, Inc. Transaction History
Pender Fund Capital Management Ltd.
- $230 Million
- Q3 2025
A detailed history of Pender Fund Capital Management Ltd. transactions in 89bio, Inc. stock. As of the latest transaction made, Pender Fund Capital Management Ltd. holds 9,400 shares of ETNB stock, worth $139,496. This represents 0.06% of its overall portfolio holdings.
Number of Shares
9,400Holding current value
$139,496% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding ETNB
# of Institutions
236Shares Held
156MCall Options Held
774KPut Options Held
6.48M-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million5.01% of portfolio
-
Pentwater Capital Management LP Naples, FL11.8MShares$174 Million1.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.36MShares$139 Million4.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.1MShares$135 Million0.22% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.28MShares$123 Million3.65% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $690M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...